Argenx SE Lists on Nasdaq, Seeks FDA Priority Review for Pediatric gMG
What happened
Argenx SE is listed on Nasdaq and is applying for FDA priority review for pediatric gMG, targeting a February 2027 action date. The company reported third-quarter 2026 global product net sales of $1.72 billion, which was a 54% increase from the same period in 2025. Management also stated that the sBLA for VYVGART Hytrulo in IMNM is on track for submission by year-end 2026.
From dailypolitical.com
Why it matters
The company's Q3 2026 product net sales reached $1.72 billion, supported by operating profit of $486 million. The pursuit of FDA priority review and several clinical milestones, such as Phase 3 MMN data for empasiprubart expected in December 2026, support the company's potential to expand its immunology platform.
From dailypolitical.com
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Center for Devices and Radiological HealthSpeculative
The successful approval of new treatments could increase market demand for specialized pharmaceutical products.